PDS Biotechnology (PDSB) 10-Q 1 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 25, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Edge Therapeutics, Inc.
Entity Central Index Key	1,472,091
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		31,246,231
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 74,996,609	$ 88,067,647
Prepaid expenses and other current assets	917,065	986,680
Total current assets	75,913,674	89,054,327
Property and equipment, net	552,757	3,423,880
Other assets	142,870	142,870
Total assets	76,609,301	92,621,077
Current liabilities:
Accounts payable	2,957,284	4,369,133
Accrued expenses	8,472,881	5,422,205
Short term debt	20,900,000	3,075,421
Total current liabilities	32,330,165	12,866,759
Noncurrent liability:
Long term debt	0	17,382,907
STOCKHOLDERS' EQUITY
Preferred stock, 5,000,000 shares authorized at March 31, 2018 and December 31, 2017, 0 outstanding	0	0
Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2018 and December 31, 2017, 31,246,231 shares and 30,869,205 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	10,524	10,400
Additional paid-in capital	217,057,074	214,309,370
Accumulated deficit	(172,788,462)	(151,948,359)
Total stockholders' equity	44,279,136	62,371,411
Total liabilities and stockholders' equity	$ 76,609,301	$ 92,621,077

Condensed Balance Sheets (Unau3

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
STOCKHOLDERS' EQUITY
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00033	$ 0.00033
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	31,246,231	30,869,205
Common stock, shares outstanding (in shares)	31,246,231	30,869,205

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Research and development expenses	$ 12,742,085	$ 7,589,496
General and administrative expenses	4,681,516	4,201,842
Impairment charges	2,672,581	0
Total operating expenses	20,096,182	11,791,338
Loss from operations	(20,096,182)	(11,791,338)
Other income (expense):
Interest income	246,639	96,259
Interest expense	(990,560)	(475,141)
Net loss	(20,840,103)	(12,170,220)
Comprehensive loss	$ (20,840,103)	$ (12,170,220)
Loss per share basic and diluted (in dollars per share)	$ (0.67)	$ (0.42)
Weighted average common shares outstanding basic and diluted (in shares)	30,965,874	28,998,616

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (20,840,103)	$ (12,170,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,985,786	1,485,705
Stock-based 401K company common match	40,847	121,620
Depreciation expense	48,542	42,306
Impairment of machinery and equipment	2,672,581	0
Amortization of debt discount	1,039	12,365
Amortization of debt issuance costs	125,355	27,102
Non-cash interest expense	405,278	92,549
Changes in assets and liabilities:
Prepaid expenses and other assets	219,615	255,055
Accounts payable	(1,411,849)	(943,416)
Accrued expenses	3,050,676	303,255
Net cash used in operating activities	(13,702,233)	(10,773,679)
Cash flows from investing activities:
Purchases of property and equipment	0	(89,284)
Net cash used in investing activities	0	(89,284)
Cash flows from financing activities:
Proceeds from exercise of stock options	721,195	50,960
Proceeds from exercise of warrants	0	3,745
Payments for debt issuance costs	(90,000)	0
Net cash provided by (used in) financing activities	631,195	54,705
Net decrease in cash	(13,071,038)	(10,808,258)
Cash and cash equivalents at beginning of period	88,067,647	106,398,919
Cash and cash equivalents at end of period	74,996,609	95,590,661
Cash paid for:
Interest	$ 457,499	$ 343,125

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2018
Nature of Operations [Abstract]
Nature of Operations	Note 1 – Edge Therapeutics, Inc. (the "Company") is a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. On March 28, 2018, the Company announced that a pre-specified interim analysis performed on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 in adults with aneurysmal subarachnoid hemorrhage demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study's primary endpoint, if the study were to be fully enrolled. The independent Data Monitoring Committee ("DMC") for the NEWTON 2 study recommended that the study be stopped based on this demonstration. The DMC also reported that there were no safety concerns attributed to EG-1962. Based on the DMC recommendation, the Company decided to discontinue the NEWTON 2 study and took steps to notify health authorities and clinical investigators participating in the study. The Company is in the process of performing analyses of the cumulative unblinded data from the NEWTON 2 study to better understand the basis for this outcome. On April 30, 2018, the Company announced that it is currently exploring strategic alternatives, which may include, without limitation, an acquisition of another company, acquisitions or in-licensing of products or product candidates, technologies or other assets, the sale of all or substantially all of the assets of the Company, a sale of stock, a strategic merger or other business combination transaction or other transaction between the Company and a third party. The Company has retained Piper Jaffray & Co, to serve as the financial advisor to its Board of Directors in the process. The Company does not have a defined timeline for the exploration of strategic alternatives and there can be no assurance that the process will result in any strategic alternative being announced or consummated. The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate. In the near term, the Company is reducing the scope of its operations, including the size of its workforce, in order to preserve its cash resources. From the Company's inception, it has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital. The Company's future operations are highly dependent on the success of its strategic alternatives review and any transactions and operations resulting from that process.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies (A) Unaudited interim financial statements: The interim balance sheet at March 31, 2018, the statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017, and cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), and following the requirements of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed financial statements have been prepared on the same basis as the Company's annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018 or for any other future annual or interim period. The balance sheet as of December 31, 2017 included herein was derived from the audited condensed financial statements as of that date. These condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2017. (B) Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. (C) Significant risks and uncertainties: The Company's operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the Company's review of strategic alternatives, the Company's ability to preserve its cash resources, the Company's ability to add product candidates to its pipeline, the Company's intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company's ability to raise capital. The Company currently has no commercially approved products and has ceased all research and development activities related to EG-1962 and suspended research for its other product candidates. As such, there can be no assurance that the Company's future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property. (D) Cash equivalents and concentration of cash balance: The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company's cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits. (E) Research and development: Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company's research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. Following the DMC's recommendation that the NEWTON 2 Trial for EG-1962 be stopped, the Company decided to discontinue the NEWTON 2 study and has taken steps to notify health authorities and clinical investigators participating in the study. The Company has ceased all further research and development activities for EG-1962 and suspended research for its other product candidates and implemented operating cost reductions and organizational restructurings while it seeks a strategic alternative, including a reduction in the Company's workforce, to preserve its cash resources and better align the organization with its current operating plan. (F) Patent costs: The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss. (G) Stock-based compensation: The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions, including, for stock options, the expected life of the option, and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the "simplified method," as the Company has limited historical information to develop reasonable expectations about future exercise patterns and employment duration for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of options grants. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. (H) Net loss per common share: Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the preferred stock, common stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: As of March 31, 2018 2017 Stock options to purchase Common Stock 7,341,468 6,193,461 Warrants to purchase Common Stock 78,596 403,782 Total 7,420,064 6,597,243 (I) Accounting standards not yet adopted: In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, "Leases (Topic 842)." The new standard requires organizations that lease assets—referred to as "lessees"—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases (see Note 9). This standard is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the impact of adoption. (J) Accounting standards adopted: In March 2016, the FASB issued ASU No. 2016-09 which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Public companies were required to adopt this standard in annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted this ASU on January 1, 2017. The impact of adopting ASU 2016-09 resulted in the following: ● The Company recognized $84,786 of tax benefit along with a full valuation allowance as of the adoption date related to the historical excess tax benefits from historical option exercises related to employee equity award activity. ● The Company elected to recognize forfeitures as they occur. The cumulative effect adjustment as a result of the adoption of this amendment on a modified retrospective basis was not material. There were no other material impacts to the Company's condensed financial statements as a result of adopting this updated standard.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2018
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments There were no transfers among Levels 1, 2, or 3 during 2018 or 2017. Fair Value Measurements at Reporting Date Using Total Quoted Prices in Active Markets (Level 1) Quoted Prices in Inactive Markets (Level 2) Significant Unobservable Inputs (Level 3) As of March 31, 2018: (unaudited) Cash and cash equivalents $ 74,996,609 $ 74,996,609 $ - $ - As of December 31, 2017: Cash and cash equivalents $ 88,067,647 $ 88,067,647 $ - $ -

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2018
Property and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment In March 2018, following the recommendation of the Data Monitoring Committee, the company made the decision to close down the EG-1962 Newton 2 study. The company believes that it would highly be unlikely that the company would be able to use the manufacturing equipment for future use. As a result, the company has taken an equipment impairment charge of $2,672,581. The write-down would bring down the value of the equipment to the Company's best estimate of its future value based on a range of estimates from a third-party seller. The equipment is being classified as Other Current Assets on the condensed balance sheet.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2018
Accrued Expenses [Abstract]
Accrued Expenses	Note 5 – Accrued Expenses Accrued expenses and other liabilities consist of the following: As of March 31, 2018 As of December 31, 2017 Accrued research and development costs (1) $ 7,729,749 $ 2,857,025 Accrued professional fees 245,773 267,646 Accrued compensation 102,715 1,886,638 Accrued other 367,336 385,896 Deferred rent 27,308 25,000 Total $ 8,472,881 $ 5,422,205 (1) Balance as of March 31, 2018 includes estimated close down NEWTON 2 trial costs of $2.9 million and $2.0 million for CMO milestone payments.

Stock Options

Stock Options	3 Months Ended
	Mar. 31, 2018
Stock Options [Abstract]
Stock Options	Note 6 – Stock Options The Company has three equity compensation plans: the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan and the 2014 Equity Incentive Plan (the "Plans"). Originally, the Company was able to grant up to 548,206 and 1,096,411 shares of Common Stock as both incentive stock options ("ISOs") and nonqualified stock options ("NQs") under the 2010 Equity Incentive Plan and the 2012 Equity Incentive Plan, respectively. In 2013, the Company's stockholders approved an increase to 1,279,146 shares authorized for issuance under the 2010 Equity Incentive Plan. In 2014, the Board of Directors of the Company (the "Board") approved an increase to 1,350,412 shares authorized for issuance under the 2010 Equity Incentive Plan. In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 1,827,351 shares as both ISOs and NQs, subject to increases as hereafter described (the "Plan Limit"). In addition, on January 1, 2015 and each January 1 thereafter prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. On January 1, 2016, 2017 and 2018 the Plan Limit was increased to 3,047,323 shares, 4,204,063 shares and 5,438,831 shares, respectively. Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four year term and NQs generally vest over a three or four year term. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding. The Company issued the following non-qualified options to purchase shares of common stock to its newly appointed executives. The awards were granted outside of the Company's 2014 Equity Incentive Plan and vest over four years with 25% vesting one year following the date of hire, and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Company through each vesting date and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the applicable option agreement and employment agreement. The grant awards were made pursuant to the NASDAQ inducement grant exception as a material component of employment compensation. Issue Date 25% Vesting Date Executive Number of Options November 16, 2015 October 30, 2016 SVP, General Counsel and Secretary 80,000 November 1, 2016 October 17, 2017 Chief Operating Officer 150,000 March 1, 2017 February 28, 2018 SVP, Regulatory Affairs 80,000 November 1, 2017 October 31, 2018 Chief Financial Officer 200,000 The Company's stock-based compensation expense was recognized in operating expense as follows: Three Months Ended March 31, 2018 2017 (unaudited) Stock-Based Compensation Research and development $ 797,340 $ 608,443 General and administrative 1,188,446 877,262 Total $ 1,985,786 $ 1,485,705 The fair value of options and warrants granted during the three months ended March 31, 2018 and 2017 was estimated using the Black-Scholes option valuation model utilizing the following assumptions: Three Months Ended March 31, 2018 2017 Weighted Average Weighted Average (unaudited) Volatility 90.40 % 89.37 % Risk-Free Interest Rate 2.34 % 1.90 % Expected Term in Years 6.11 6.05 Dividend Rate 0.00 % 0.00 % Fair Value of Option on Grant Date $ 10.88 $ 6.67 The following table summarizes the number of options outstanding and the weighted average exercise price: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Aggregate Intrinsic Value Options outstanding at December 31, 2017 6,462,795 $ 6.50 Granted 1,120,100 14.42 Exercised (198,300 ) 3.64 Forfeited (43,127 ) 12.09 Options outstanding at March 31, 2018 7,341,468 $ 7.75 7.36 $ 151,247 Vested and expected to vest at March 31, 2018 7,341,467 $ 7.75 7.36 $ 151,247 Exercisable at March 31, 2018 4,280,124 $ 5.53 6.20 $ 151,247 At March 31, 2018 there was approximately $22,737,886 of unamortized stock compensation expense, which is expected to be recognized over a remaining average vesting period of 2.8 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Taxes [Abstract]
Income Taxes	Note 7 – Income Taxes In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. There was a full valuation allowance against the net deferred tax assets as of March 31, 2018 and December 31, 2017. At December 31, 2017, the Company had federal net operating loss ("NOL") carryforwards of approximately $101.5 million which expire between 2029 and 2037. At December 31, 2017, the Company had federal research and development credits carryforwards of approximately $1.9 million and an orphan drug credit carryover of approximately $22.1 million. The Company may be subject to the net operating loss utilization provisions of Section 382 of the Internal Revenue Code. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company's capital during a specified period prior to the change, and the federal published interest rate. Although the Company has not completed an analysis under Section 382 of the Code, it is likely that the utilization of the NOLs will be limited. At December 31, 2017, the Company had approximately $31.9 million of State of New Jersey NOL's which expire between 2030 and 2037. At December 31, 2017, the Company had approximately $0.4 million of the State of New Jersey research development credits carryforwards. The State of New Jersey has enacted legislation permitting certain corporations located in New Jersey to sell state tax loss carryforwards and state research and development credits, or net loss carryforwards. In 2017, the Company sold $26,097,607 of State of New Jersey NOL's and $424,466 of State of New Jersey R&D Credits for $2,586,057. In 2016, the Company sold $19,196,765 of State of New Jersey NOL's and $257,222 of State of New Jersey R&D Credits for $1,845,986. Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2017, there were no uncertain positions. The Company's U.S. federal and state net operating losses have occurred since its inception in 2009 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. In September 2017, the IRS concluded auditing the Company's 2015 tax year resulting in a no change letter. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three months ended March 31, 2018 and 2017. On December 22, 2017, H.R. 1 (also, known as the Tax Cuts and Jobs Act (the "Act")) was signed into law. Among its numerous changes to the Internal Revenue Code, the Act reduces U.S. federal corporate tax rate to 21%. As a result, the Company believes that the most significant impact on its condensed financial statements will be reduction of approximately $13.6 million for the deferred tax assets related to net operating losses and other assets. Such reduction is offset by changes to the Company's valuation allowance. The Company is also in the process of considering the impact under the Act of the disallowance of certain incentive based compensation tax deductibility under Internal Revenue Code Section 162(m). If an adjustment to the deferred tax asset is required, the impact will be offset by a corresponding adjustment to the valuation allowance.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 8 – Commitments and Contingencies Evonik The Company entered into an agreement with SurModics Pharmaceuticals, Inc. ("SurModics") in October 2010 for the exclusive worldwide licensing of certain technology, patent rights and know-how rights related to the production of EG-1962, (the "Evonik Agreement"). This agreement was later transferred to Evonik Industries AG ("Evonik") when it purchased substantially all the assets of SurModics. Pursuant to the Evonik Agreement, in exchange for the license, the Company agreed to make milestone payments totaling up to $14.75 million upon the achievement of certain development, regulatory and sales milestones detailed in the Evonik Agreement. The Company paid $0.25 million upon execution of the Evonik Agreement. In August 2016, the Company paid a milestone of $1.0 million after the first patient in the Phase 3 clinical trial of EG-1962 was dosed. In addition, the Evonik Agreement calls for the Company to pay royalties on sales of certain products based on a mid-single digit percentage of net sales. The Evonik Agreement provides for the reduction of royalties in certain limited circumstances. The term of the Evonik Agreement will continue until the expiration of the Company's obligation to pay royalties to Evonik. Either party may terminate the Evonik Agreement due to material breach by the other party. Evonik may terminate the Evonik Agreement or convert it to a non-exclusive license, in either case upon giving the Company written notice, if the Company fails to use commercially reasonable efforts to hit certain specified development, regulatory and commercial milestones. Following the discontinuation of the NEWTON 2 trial for EG-1962, the Company has ceased all research and development efforts related to EG-1962 and suspended efforts on its other product candidates as it pursues strategic alternatives. As such, unless the Company resumes such development activities, it is unlikely that the Company will have any additional milestone or royalty obligations to Evonik in the future. Oakwood Amended and Restated Master Formulation Development Agreement In June 2017, the Company entered into an Amended and Restated Master Formulation Development Agreement (the "Restated Development Agreement") with Oakwood Laboratories, L.L.C. ("Oakwood"), pursuant to which Oakwood agreed to continue to provide the Company with certain drug formulation development and non-commercial manufacturing services for EG-1962, in accordance with project plans that may be entered into from time to time. Under the Restated Development Agreement, the Company agreed to pay Oakwood to perform services under agreed upon project plans and to pay Oakwood up to an aggregate of $4.5 million. In July 2017, the Company paid $1.5 million of such aggregate amount in connection with entering into the Restated Development Agreement. Of the remaining $3.0 million of such aggregate amount, $0.5 million is payable no later than April 1, 2018 and $2.5 million is payable no later than April 1, 2019. These remaining payments may be accelerated if: (i) the Company achieves various regulatory milestones, (ii) the Company closes an equity or similar financing in excess of a predetermined amount, or (iii) there is an early termination, under certain circumstances, of the Restated Development Agreement or the Supply Agreement with Oakwood. The earned milestones have been accrued as of March 31, 2018. As additional consideration for performance under the Restated Development Agreement and the Supply Agreement (as defined below), the Company agreed to pay Oakwood a royalty, during the Royalty Term, in an amount equal to a low single digit percentage of net sales of EG-1962, regardless of the manufacturer or supplier thereof. The "Royalty Term" is the period commencing upon the commercial launch of EG-1962 by the Company and continuing until twelve (12) years following such launch. The term of the Restated Development Agreement continues until the expiration or termination of the Supply Agreement, unless earlier terminated (the "Term"). The Company has the right to terminate project plans upon the occurrence of various circumstances described in the Restated Development Agreement. In the event that the Company terminates the most recent project plan prior to completion (which would include the Company's recent decision to discontinue the development or commercialization of EG-1962), the Company must pay to Oakwood a termination fee for work completed which has been accrued as of March 31, 2018. Oakwood Manufacturing and Supply Agreement Concurrent with its entry into the Restated Development Agreement, on June 30, 2017, the Company entered into a Manufacturing and Supply Agreement with Oakwood (the "Supply Agreement"), pursuant to which Oakwood agreed to manufacture and supply, and the Company agreed to purchase from Oakwood, EG-1962 in commercial quantities following the commercial launch of the product. Pursuant to the Supply Agreement, the Company agreed to pay Oakwood milestone payments that could total up to an aggregate of $2.25 million upon the achievement of certain development and regulatory milestones. The term of the Supply Agreement will terminate automatically upon the termination of the Restated Development Agreement for any reason. Additionally, either party may terminate the Supply Agreement upon a material breach by the other party that fails to be cured in the applicable cure period. Following the discontinuation of the NEWTON 2 trial for EG-1962, the Company has ceased all research and development efforts related to EG-1962 and suspended efforts on its other product candidates. As such the Company may terminate the Supply Agreement immediately upon notice to Oakwood (which will also result in the automatic termination of the Restated Development Agreement); provided, that if it chooses to do so prior to completion of the most recent project plan attached to the Restated Development Agreement, the Company must pay to Oakwood a termination fee. While certain of the Company's milestone payments to Oakwood will remain outstanding (including the termination fee in the event the Restated Development Agreement is terminated), unless the Company resumes such development activities, it is unlikely that the Company will be required to pay additional milestone or royalty payments to Oakwood in the future pursuant to the Restated Development Agreement or the Supply Agreement. Class Action Civil Litigation On April 23, 2018, a purported securities class action complaint was filed against the Company, Brian Leuthner (the Company's President and Chief Executive Officer) and Andrew Saik (the Company's Chief Financial Officer) in the United States District Court for the District of New Jersey, Sanfilippo v. Edge Therapeutics, Inc. Employment Agreements The Company has entered into employment agreements with each of its executive officers. The agreements generally provide for, among other things, salary, bonus and severance payments. The employment agreements generally provide for between 12 months and 18 months of severance benefits to be paid to an executive (as well as certain potential bonus, COBRA and equity award benefits), subject to the effectiveness of a general release of claims, if the executive terminates his or her employment for good reason or if the Company terminates the executive's employment without cause. Such severance payments may be provided for as long as 24 months in connection with a termination following a change of control. The continued provision of severance benefits is conditioned on each executive's compliance with the terms of the Company's confidentiality and invention and assignment agreement as well as his or her release of claims. Leases Effective December 13, 2013, the Company entered into a 63 month lease for approximately 8,000 square feet of office space in Berkeley Heights, New Jersey. On February 18, 2016, the Company entered into a new 63 month lease for approximately 20,410 square feet of office space within the same office complex in Berkeley Heights, New Jersey. The terms of the new lease were structured so that the termination date of the December 13, 2013 lease coincided with the commencement date of the new lease on August 13, 2016. As a result of the lease termination, the Company wrote off $67,118 of leasehold improvements. Rent expense is recognized on a straight line basis where there are escalating payments, and was approximately $152,026 and $148,060 for the three months ended March 31, 2018 and 2017, respectively. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2018: Year ended December 31, 2018 (remaining) $ 452,164 2019 604,541 2020 603,371 2021 530,386 2022 and after - Total minimum payments required $ 2,190,462

Debt

Debt	3 Months Ended
	Mar. 31, 2018
Debt [Abstract]
Debt	Note 9 – Debt On August 28, 2014, the Company entered into a loan and security agreement with Hercules Technology Growth Capital, Inc., (the "Original Loan Agreement"). The Original Loan Agreement provided funding for an aggregate principal amount of up to $10,000,000 in three separate term loans. The Wall Street Journal The Wall Street Journal Commencing in October 2015, the term loans began amortizing in equal monthly installments of principal and interest over 30 months. On the maturity date or the date the loan otherwise became due and payable, the Company was also required to make a payment equal to 1.5% of the total amounts funded under the Original Loan Agreement. On August 1, 2016, the Company entered into an Amended and Restated Loan and Security Agreement (the "Amended Loan Agreement") with Hercules Capital, Inc., formerly known as Hercules Technology Growth Capital, Inc. ("Hercules"). Pursuant to the Amended Loan Agreement, the Company was able to borrow up to $20,000,000. At closing, the Company borrowed $15,000,000 of the amount available for draw under the Amended Loan Agreement (and received proceeds net of the amount then outstanding under the Original Loan Agreement, fees and expenses). On May 23, 2017, the Company elected to draw down the second tranche of $5 million. Amounts drawn under the Amended Loan Agreement bear interest at a rate per annum equal to the greater of either (i) the sum of (a) 9.15%, plus (b) the prime rate as reported in The Wall Street Journal Pursuant to the Amended Loan Agreement, in March 2018, the Company made a payment of $90,000, which is equal to 1.5% of the total amounts funded under the Original Loan Agreement. On the maturity date or the date the loan otherwise becomes due and payable, under the Amended Loan Agreement the Company must also make a payment of $900,000, which is equal to 4.5% of the total amounts available under the Amended Loan Agreement. Hercules has the right to accelerate the Company's outstanding obligation due to the material adverse change. As a result, the entire amount of $900,000 has been recorded as of March 31, 2018. In addition, if the Company prepays the term loan (i) during the first year following the initial closing, the Company must pay a prepayment charge equal to 2% of the amount being prepaid, (ii) during the second year following the closing, the Company must pay a prepayment charge equal to 1% of the amount being prepaid, and (iii) after the second year following the closing, the Company must pay a prepayment charge equal to 0.5% of the amount being prepaid. The loan is secured by substantially all of the Company's assets, other than intellectual property, which is the subject of a negative pledge. Under the Amended Loan Agreement, the Company is subject to certain customary covenants that limit or restrict the Company's ability to, among other things, incur additional indebtedness, investments, distributions, transfer assets, make acquisitions, grant any security interests, pay cash dividends, repurchase its Common Stock, make loans, or enter into certain transactions without prior consent. The Amended Loan Agreement contains several events of default, including, among others, payment defaults, breaches of covenants or representations, material impairment in the perfection of Hercules' security interest or in the collateral and events related to bankruptcy or insolvency, including a material adverse change in the prospects of the Company. Upon an event of default, Hercules may declare all outstanding obligations immediately due and payable (along with a prepayment charge), a default rate of an additional 5.0% may be applied to the outstanding loan balances, and Hercules may take such further actions as set forth in the Amended Loan Agreement, including collecting or taking such other action with respect to the collateral pledged in connection with the Amended Loan Agreement. The Company has discussed its decision to halt its NEWTON 2 clinical trial and its ceasing research and development activities for its EG-1962 and suspension of its other product candidates with Hercules, an event that may be considered a material adverse change in the prospects of the Company, Hercules has not declared an event of default or indicated that it will accelerate the Company's $20,000,000 outstanding obligations. Since Hercules may have the right to accelerate the Company's outstanding obligations, the Company has reclassified these obligations, including the $900,000 end of facility payment described above, from long term debt to short term debt. Hercules has informed the Company that it will defer discussion on the debt until late in the second quarter of 2018 as to allow the Company a period of time to conduct its strategic review process. Future principal payments prior to any material adverse change event on the note as of March 31, 2018 were as follows: Year Ending in December 31: (000's) 2018 (remaining) $ 3,069 2019 9,817 2020 7,114 2021 - Total $ 20,000 The estimated fair value of the debt (categorized as a Level 2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. The Company believes the estimated fair value at March 31, 2018 approximates the carrying amount.

Retirement Plan

Retirement Plan	3 Months Ended
	Mar. 31, 2018
Retirement Plan [Abstract]
Retirement Plan	Note 10 – Retirement Plan The Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401K employer contributions were

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events On May 1, 2018, the Company announced a planned reduction in its workforce as a result of stopping its NEWTON 2 clinical trial for EG-1962 and suspending the related manufacturing activities. The Company will reduce its headcount from 37 to 8 employees and result in a severance charge of $3.724 million.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Unaudited Interim Financial Statements	(A) Unaudited interim financial statements: The interim balance sheet at March 31, 2018, the statements of operations and comprehensive loss for the three months ended March 31, 2018 and 2017, and cash flows for the three months ended March 31, 2018 and 2017 are unaudited. The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), and following the requirements of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed financial statements have been prepared on the same basis as the Company's annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018 or for any other future annual or interim period. The balance sheet as of December 31, 2017 included herein was derived from the audited condensed financial statements as of that date. These condensed financial statements should be read in conjunction with the Company's audited financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2017.
Use of Estimates	(B) Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant Risks and Uncertainties	(C) Significant risks and uncertainties: The Company's operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the Company's review of strategic alternatives, the Company's ability to preserve its cash resources, the Company's ability to add product candidates to its pipeline, the Company's intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the Company's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company's ability to raise capital. The Company currently has no commercially approved products and has ceased all research and development activities related to EG-1962 and suspended research for its other product candidates. As such, there can be no assurance that the Company's future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.
Cash Equivalents and Concentration of Cash Balance	(D) Cash equivalents and concentration of cash balance: The Company considers all highly liquid securities with a maturity weighted average of less than three months to be cash equivalents. The Company's cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.
Research and Development	(E) Research and development: Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company's research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred. Following the DMC's recommendation that the NEWTON 2 Trial for EG-1962 be stopped, the Company decided to discontinue the NEWTON 2 study and has taken steps to notify health authorities and clinical investigators participating in the study. The Company has ceased all further research and development activities for EG-1962 and suspended research for its other product candidates and implemented operating cost reductions and organizational restructurings while it seeks a strategic alternative, including a reduction in the Company's workforce, to preserve its cash resources and better align the organization with its current operating plan.
Patent Costs	(F) Patent costs: The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.
Stock-Based Compensation	(G) Stock-based compensation: The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions, including, for stock options, the expected life of the option, and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the "simplified method," as the Company has limited historical information to develop reasonable expectations about future exercise patterns and employment duration for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of options grants. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option.
Net Loss per Common Share	(H) Net loss per common share: Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the preferred stock, common stock options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: As of March 31, 2018 2017 Stock options to purchase Common Stock 7,341,468 6,193,461 Warrants to purchase Common Stock 78,596 403,782 Total 7,420,064 6,597,243
Accounting Standards Not Yet Adopted	(I) Accounting standards not yet adopted: In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, "Leases (Topic 842)." The new standard requires organizations that lease assets—referred to as "lessees"—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases (see Note 9). This standard is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the impact of adoption.
Accounting Standards Adopted	(J) Accounting standards adopted: In March 2016, the FASB issued ASU No. 2016-09 which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Public companies were required to adopt this standard in annual reporting periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted this ASU on January 1, 2017. The impact of adopting ASU 2016-09 resulted in the following: ● The Company recognized $84,786 of tax benefit along with a full valuation allowance as of the adoption date related to the historical excess tax benefits from historical option exercises related to employee equity award activity. ● The Company elected to recognize forfeitures as they occur. The cumulative effect adjustment as a result of the adoption of this amendment on a modified retrospective basis was not material. There were no other material impacts to the Company's condensed financial statements as a result of adopting this updated standard.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive: As of March 31, 2018 2017 Stock options to purchase Common Stock 7,341,468 6,193,461 Warrants to purchase Common Stock 78,596 403,782 Total 7,420,064 6,597,243

Fair Value of Financial Instr19

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	There were no transfers among Levels 1, 2, or 3 during 2018 or 2017. Fair Value Measurements at Reporting Date Using Total Quoted Prices in Active Markets (Level 1) Quoted Prices in Inactive Markets (Level 2) Significant Unobservable Inputs (Level 3) As of March 31, 2018: (unaudited) Cash and cash equivalents $ 74,996,609 $ 74,996,609 $ - $ - As of December 31, 2017: Cash and cash equivalents $ 88,067,647 $ 88,067,647 $ - $ -

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2018
Accrued Expenses [Abstract]
Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consist of the following: As of March 31, 2018 As of December 31, 2017 Accrued research and development costs (1) $ 7,729,749 $ 2,857,025 Accrued professional fees 245,773 267,646 Accrued compensation 102,715 1,886,638 Accrued other 367,336 385,896 Deferred rent 27,308 25,000 Total $ 8,472,881 $ 5,422,205 (1) Balance as of March 31, 2018 includes estimated close down NEWTON 2 trial costs of $2.9 million and $2.0 million for CMO milestone payments.

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended
	Mar. 31, 2018
Stock Options [Abstract]
Non-Qualified Stock Options	The grant awards were made pursuant to the NASDAQ inducement grant exception as a material component of employment compensation. Issue Date 25% Vesting Date Executive Number of Options November 16, 2015 October 30, 2016 SVP, General Counsel and Secretary 80,000 November 1, 2016 October 17, 2017 Chief Operating Officer 150,000 March 1, 2017 February 28, 2018 SVP, Regulatory Affairs 80,000 November 1, 2017 October 31, 2018 Chief Financial Officer 200,000
Stock-Based Compensation Expense	The Company's stock-based compensation expense was recognized in operating expense as follows: Three Months Ended March 31, 2018 2017 (unaudited) Stock-Based Compensation Research and development $ 797,340 $ 608,443 General and administrative 1,188,446 877,262 Total $ 1,985,786 $ 1,485,705
Assumptions Used to Value Stock Options and Warrants Granted	The fair value of options and warrants granted during the three months ended March 31, 2018 and 2017 was estimated using the Black-Scholes option valuation model utilizing the following assumptions: Three Months Ended March 31, 2018 2017 Weighted Average Weighted Average (unaudited) Volatility 90.40 % 89.37 % Risk-Free Interest Rate 2.34 % 1.90 % Expected Term in Years 6.11 6.05 Dividend Rate 0.00 % 0.00 % Fair Value of Option on Grant Date $ 10.88 $ 6.67
Stock Option Activity	The following table summarizes the number of options outstanding and the weighted average exercise price: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life in Years Aggregate Intrinsic Value Options outstanding at December 31, 2017 6,462,795 $ 6.50 Granted 1,120,100 14.42 Exercised (198,300 ) 3.64 Forfeited (43,127 ) 12.09 Options outstanding at March 31, 2018 7,341,468 $ 7.75 7.36 $ 151,247 Vested and expected to vest at March 31, 2018 7,341,467 $ 7.75 7.36 $ 151,247 Exercisable at March 31, 2018 4,280,124 $ 5.53 6.20 $ 151,247

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies [Abstract]
Future Minimum Rental Payments Required under Operating Leases	The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2018: Year ended December 31, 2018 (remaining) $ 452,164 2019 604,541 2020 603,371 2021 530,386 2022 and after - Total minimum payments required $ 2,190,462

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Debt [Abstract]
Future Principal Payments	Future principal payments prior to any material adverse change event on the note as of March 31, 2018 were as follows: Year Ending in December 31: (000's) 2018 (remaining) $ 3,069 2019 9,817 2020 7,114 2021 - Total $ 20,000

Nature of Operations (Details)

Nature of Operations (Details) - Subject	3 Months Ended
	Mar. 31, 2018	Mar. 28, 2018
Nature of Operations [Abstract]
Number of days of treatment received by subjects prior to pre-specified interim analysis	90 days
Number of subjects randomized and treated first in Phase 3 NEWTON 2 study of EG-1962		210

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Net Loss per Common Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,420,064	6,597,243
Stock Options to Purchase Common Stock [Member]
Net Loss per Common Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,341,468	6,193,461
Warrants to Purchase Common Stock [Member]
Net Loss per Common Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	78,596	403,782
ASU 2016 - 09 [Member]
Accounting Standards Adopted [Abstract]
Tax benefit			$ (84,786)

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Fair Value Transfers Between Levels [Abstract]
Transfers from Level 1 to Level 2	$ 0	$ 0
Transfers from Level 2 to Level 1	0	0
Transfers into Level 3	0	0
Transfers out of Level 3	0	0
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	74,996,609	88,067,647
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	74,996,609	88,067,647
Quoted Prices in Inactive Markets (Level 2) [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value of Financial Instruments [Abstract]
Cash and cash equivalents	$ 0	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property and Equipment [Abstract]
Equipment impairment charge	$ 2,672,581	$ 0

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Mar. 31, 2018		Dec. 31, 2017
Accrued Expenses [Abstract]
Accrued research and development costs	$ 7,729,749	[1]	$ 2,857,025
Accrued professional fees	245,773		267,646
Accrued compensation	102,715		1,886,638
Accrued other	367,336		385,896
Deferred rent	27,308		25,000
Total	8,472,881		$ 5,422,205
Accrued close down NEWTON 2 trial costs	2,900,000
Accrued CMO milestone payments	$ 2,000,000
[1]	Balance as of March 31, 2018 includes estimated close down NEWTON 2 trial costs of $2.9 million and $2.0 million for CMO milestone payments.

Stock Options, Equity Compensat

Stock Options, Equity Compensation Plans (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2018Plan	Dec. 31, 2014shares	Jan. 02, 2018shares	Jan. 02, 2017shares	Jan. 02, 2016shares	Dec. 31, 2013shares	Dec. 31, 2012shares	Dec. 31, 2010shares
Stock Options [Abstract]
Number of equity compensation plans | Plan	3
The Plans [Member]
Stock Options [Abstract]
Term of plan	10 years
The Plans [Member] | Incentive Stock Options [Member]
Stock Options [Abstract]
Vesting period	4 years
The Plans [Member] | Incentive Stock Options [Member] | Maximum [Member]
Stock Options [Abstract]
Term of option	10 years
The Plans [Member] | Nonqualified Options [Member] | Minimum [Member]
Stock Options [Abstract]
Vesting period	3 years
The Plans [Member] | Nonqualified Options [Member] | Maximum [Member]
Stock Options [Abstract]
Vesting period	4 years
2010 Equity Incentive Plan [Member]
Stock Options [Abstract]
Number of shares authorized for issuance (in shares)		1,350,412				1,279,146		548,206
2012 Equity Incentive Plan [Member]
Stock Options [Abstract]
Number of shares authorized for issuance (in shares)							1,096,411
2014 Equity Incentive Plan [Member]
Stock Options [Abstract]
Number of shares authorized for issuance (in shares)		1,827,351	5,438,831	4,204,063	3,047,323
Percentage of Common Stock outstanding used to determine annual increase in the plan limit		4.00%

Stock Options, Non-qualified Op

Stock Options, Non-qualified Options (Details) - Nonqualified Stock Options [Member]	Nov. 01, 2017shares	Mar. 01, 2017shares	Nov. 01, 2016shares	Nov. 16, 2015shares	Mar. 31, 2018Installment
Executives [Member]
Stock Options [Abstract]
Vesting period					4 years
Executives [Member] | Vesting One Year Following Date of Hire [Member]
Stock Options [Abstract]
Vesting percentage					25.00%
Executives [Member] | Vesting in 36 Monthly Installments Thereafter [Member]
Stock Options [Abstract]
Vesting percentage					75.00%
Number of monthly installments for vesting | Installment					36
SVP, General Counsel and Secretary [Member]
Stock Options [Abstract]
Issue date					Nov. 16, 2015
25% vesting date					Oct. 30, 2016
Number of options (in shares)				80,000
Chief Operating Officer [Member]
Stock Options [Abstract]
Issue date					Nov. 1, 2016
25% vesting date					Oct. 17, 2017
Number of options (in shares)			150,000
SVP, Regulatory Affairs [Member]
Stock Options [Abstract]
Issue date					Mar. 1, 2017
25% vesting date					Feb. 28, 2018
Number of options (in shares)		80,000
Chief Financial Officer [Member]
Stock Options [Abstract]
Issue date					Nov. 1, 2017
25% vesting date					Oct. 31, 2018
Number of options (in shares)	200,000

Stock Options, Stock-Based Comp

Stock Options, Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 1,985,786	$ 1,485,705
Research and Development [Member]
Stock-Based Compensation [Abstract]
Stock-based compensation expense	797,340	608,443
General and Administrative [Member]
Stock-Based Compensation [Abstract]
Stock-based compensation expense	$ 1,188,446	$ 877,262

Stock Options, Assumptions Used

Stock Options, Assumptions Used to Value Stock Options and Warrants Granted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]
Volatility	90.40%	89.37%
Risk-free interest rate	2.34%	1.90%
Expected term	6 years 1 month 10 days	6 years 18 days
Dividend rate	0.00%	0.00%
Fair value of option on grant date (in dollars per share)	$ 10.88	$ 6.67

Stock Options, Stock Option Act

Stock Options, Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Unamortized Stock Compensation Expense [Abstract]
Unamortized stock compensation expense | $	$ 22,737,886
Period for recognition	2 years 9 months 18 days
Stock Options [Member]
Number of Shares [Roll Forward]
Options outstanding, beginning balance (in shares) | shares	6,462,795
Granted (in shares) | shares	1,120,100
Exercised (in shares) | shares	(198,300)
Forfeited (in shares) | shares	(43,127)
Options outstanding, ending balance (in shares) | shares	7,341,468
Vested and expected to vest (in shares) | shares	7,341,467
Exercisable (in shares) | shares	4,280,124
Weighted Average Exercise Price [Roll Forward]
Options outstanding, beginning balance (in dollars per share) | $ / shares	$ 6.50
Granted (in dollars per share) | $ / shares	14.42
Exercised (in dollars per share) | $ / shares	3.64
Forfeited (in dollars per share) | $ / shares	12.09
Options outstanding, ending balance (in dollars per share) | $ / shares	7.75
Vested and expected to vest (in dollars per share) | $ / shares	7.75
Exercisable (in dollars per share) | $ / shares	$ 5.53
Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]
Options outstanding, weighted average remaining contractual life	7 years 4 months 10 days
Vested and expected to vest, weighted average remaining contractual life	7 years 4 months 10 days
Exercisable, weighted average remaining contractual life	6 years 2 months 12 days
Options outstanding, aggregate intrinsic value | $	$ 151,247
Vested and expected to vest, aggregate intrinsic value | $	151,247
Exercisable, aggregate intrinsic value | $	$ 151,247

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Income Taxes [Abstract]
Uncertain tax positions		$ 0
Unrecognized tax benefits	$ 0			$ 0
Accrued interest and penalties	$ 0			$ 0
Federal statutory rate	21.00%
Reduction in deferred tax assets due to Tax Cuts and Jobs Act	$ 13,600,000
Federal [Member]
Income Taxes [Abstract]
Net operating loss carryforwards		101,500,000
Federal [Member] | Minimum [Member]
Income Taxes [Abstract]
Expiration date of net operating loss carryforwards	Dec. 31, 2029
Federal [Member] | Maximum [Member]
Income Taxes [Abstract]
Expiration date of net operating loss carryforwards	Dec. 31, 2037
New Jersey [Member]
Income Taxes [Abstract]
Net operating loss carryforwards		31,900,000
NOL's sold		26,097,607	$ 19,196,765
Proceeds from sale of NOL's and R&D tax credits		2,586,057	1,845,956
New Jersey [Member] | Minimum [Member]
Income Taxes [Abstract]
Expiration date of net operating loss carryforwards	Dec. 31, 2030
New Jersey [Member] | Maximum [Member]
Income Taxes [Abstract]
Expiration date of net operating loss carryforwards	Dec. 31, 2037
Research and Development Credit [Member] | Federal [Member]
Income Taxes [Abstract]
Tax credit carryforwards		1,900,000
Research and Development Credit [Member] | New Jersey [Member]
Income Taxes [Abstract]
Tax credit carryforwards		400,000
Tax credit carryforwards sold		424,466	$ 257,222
Orphan Drug Credit [Member] | Federal [Member]
Income Taxes [Abstract]
Tax credit carryforwards		$ 22,100,000

Commitments and Contingencies35

Commitments and Contingencies (Details)	1 Months Ended			3 Months Ended
	Jul. 31, 2017USD ($)	Aug. 31, 2016USD ($)	Oct. 31, 2010USD ($)	Mar. 31, 2018USD ($)ft²	Mar. 31, 2017USD ($)
Leases [Abstract]
Rent expense				$ 152,026	$ 148,060
Future Minimum Rental Payments Required under Operating Leases [Abstract]
2018 (remaining)				452,164
2,019				604,541
2,020				603,371
2,021				530,386
2022 and after				0
Total minimum payments required				2,190,462
Evonik [Member]
Commitments and Contingencies [Abstract]
Milestone payments paid		$ 1,000,000	$ 250,000
Evonik [Member] | Maximum [Member]
Commitments and Contingencies [Abstract]
Milestone payments to be paid				14,750,000
Oakwood Amended and Restated Master Formulation Development Agreement [Member]
Commitments and Contingencies [Abstract]
Milestone payments paid	$ 1,500,000
Remaining milestone payments to be paid				3,000,000
Remaining milestone payments to be paid no later than April 1, 2018				500,000
Remaining milestone payments to be paid no later than April 1, 2019				$ 2,500,000
Royalty Term				12 years
Oakwood Amended and Restated Master Formulation Development Agreement [Member] | Maximum [Member]
Commitments and Contingencies [Abstract]
Milestone payments to be paid				$ 4,500,000
Oakwood Manufacturing and Supply Agreement [Member] | Maximum [Member]
Commitments and Contingencies [Abstract]
Milestone payments to be paid				$ 2,250,000
Employment Agreements [Member]
Commitments and Contingencies [Abstract]
Term for payment of severance benefits following a change of control				24 months
Employment Agreements [Member] | Minimum [Member]
Commitments and Contingencies [Abstract]
Term for payment of severance benefits				12 months
Employment Agreements [Member] | Maximum [Member]
Commitments and Contingencies [Abstract]
Term for payment of severance benefits				18 months
Office Space in Berkeley Heights, New Jersey Under Lease Effective December 13, 2013 [Member]
Leases [Abstract]
Term of lease				63 months
Area of leased property | ft²				8,000
Writeoff of leasehold improvements				$ 67,118
Office Space in Berkeley Heights, New Jersey Under Lease Entered into February 18, 2016 [Member]
Leases [Abstract]
Term of lease				63 months
Area of leased property | ft²				20,410

Debt (Details)

Debt (Details)	May 23, 2017USD ($)	Aug. 01, 2016USD ($)	Apr. 06, 2015	Aug. 28, 2014USD ($)Loan	Mar. 31, 2018USD ($)	Jan. 31, 2018	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)	Jun. 30, 2015USD ($)	Jan. 29, 2015USD ($)
Loan and Security Agreement [Abstract]
Payments for debt issuance costs							$ 90,000	$ 0
Short term debt					$ 20,900,000		20,900,000		$ 3,075,421
Future Principal Payments [Abstract]
2018 (remaining)					3,069,000		3,069,000
2,019					9,817,000		9,817,000
2,020					7,114,000		7,114,000
2,021					0		0
Total					$ 20,000,000		$ 20,000,000
Original Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Aggregate principal amount of borrowing capacity				$ 10,000,000
Number of term loans | Loan				3
Interest rate			9.95%	10.45%
Adjustment to interest rate			(4.50%)	(4.50%)
Term for making principal and interest payments							30 months
Additional interest rate charged on due date				1.50%	1.50%
Payments for debt issuance costs					$ 90,000
First Term Loan under Original Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Face amount				$ 3,000,000
Maturity date							Mar. 1, 2018
Second Term Loan under Original Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Face amount											$ 3,000,000
Maturity date							Mar. 1, 2018
Third Term Loan under Original Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Unused borrowing capacity										$ 4,000,000
Amended Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Aggregate principal amount of borrowing capacity		$ 20,000,000
Maturity date							Feb. 3, 2020
Term for making principal and interest payments							24 months
Additional interest rate charged on due date		4.50%
Effective interest rate					9.40%		9.40%
Period to extend interest-only payments at lender's discretion						6 months
Additional interest charged on due date		$ 900,000
Short term debt					$ 900,000		$ 900,000
Prepayment charge during first year following initial closing		2.00%
Prepayment charge during second year following initial closing		1.00%
Prepayment charge after second year following initial closing		0.50%
Event of default rate		5.00%
Amended Loan Agreement [Member] | Maximum [Member]
Loan and Security Agreement [Abstract]
Maturity date							Aug. 3, 2020
First Term Loan under Amended Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Face amount		$ 15,000,000
Second Term Loan under Amended Loan Agreement [Member]
Loan and Security Agreement [Abstract]
Face amount	$ 5,000,000
Interest rate	9.15%
Adjustment to interest rate	(4.50%)

Retirement Plan (Details)

Retirement Plan (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Retirement Plan [Abstract]
401(k) employer contribution	$ 82,715	$ 121,620

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] $ in Thousands	May 01, 2018USD ($)Employee	Apr. 30, 2018Employee
Subsequent Events [Abstract]
Number of employees | Employee	8	37
Severance charge | $	$ 3,724